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Articular cartilage repair techniques exploiting intrinsic 
healing capacity – which one is the best?
Abstract
In this review article articular cartilage structure and organization is 
explained, followed by brief discussion on articular cartilage focal lesion 
development and subsequent endogenous regeneration, which mainly relies 
on presence of intrinsic healing capacity. In case of full thickness focal chon-
dral defects intrinsic healing ability is insufficient and full spontaneous re-
pair is almost never achieved. In those cases, cartilage repair techniques are 
indicated. 
Currently, the most commonly used articular cartilage repair techniques 
include three groups of techniques such as: bone marrow stimulation, osteo-
chondral allografting/autografting and autologous chondrocyte implanta-
tion. These groups are further divided to specific cartilage repair techniques, 
discussed in detail and compared to other approaches. The information pro-
vided is intended to allow proper critical judgment and to answer the ques-




Articular cartilage represents a highly specialized avascular and an-eural connective tissue, thick between 2 to 4 mm, which lines the 
joint surface and provides sophisticated low friction mechanical system 
allowing smooth joint motion under full weight bearing. It is comprised 
primarily of water (60-85%), type II collagen (15-22 %) and the proteo-
glycan aggrecan (4-7%) with addition of other extracellular matrix com-
ponents including other collagen types (VI, IX, X, XI), small proteo-
glycans (decorin, biglycan and fibromodulin (1)) and glycoproteins (e.g. 
chondronectin) (2- 4). Only one cell type is present within the cartilage 
- chondrocytes, constituting only 2% of the total volume of articular 
cartilage (5). The articular hyaline cartilage possesses well-known zonal 
architecture, since different distribution of cells, matrix, and mechanical 
properties are present when observing different cartilage depths (6). 
Four zones of articular cartilage are: superficial zone, middle zone, deep 
zone and calcified cartilage zone, underneath which subchondral bone 
is situated (Figure 1). Within each zone, 3 additional regions can be 
identified - the pericellular, territorial, and inter-territorial regions (7).
Superficial zone - is the thinnest upper-most cartilage zone, and it is 
comprised of two layers: a fibrilar sheet covering joint surface and cel-
lular layer of flattened chondrocytes with axes parallel to the articular 
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centration. Superficial zone has the highest water content 
compared to the other zones (80% of total cartilage mass) 
(8, 9). Middle (transitional) zone is situated under super-
ficial zone, representing transition between the shearing 
forces of surface layer to compression forces in the deeper 
cartilage layers. Middle zone is considerably thicker than 
superficial zone with spheroid cells synthetizing mostly 
proteoglycan component of the matrix together with 
smaller proportion of thick collagen fibrils, while water 
content remains relatively low. This zone accounts for ap-
proximately 40% to 60% of the total cartilage volume. 
Deep zone of the hyaline cartilage is situated under middle 
zone, presenting around 30% of hyaline cartilage volume. 
In this zone chondrocytes are organized into columns 
lying perpendicular to the joint surface. This layer pro-
vides the greatest resistance of the articular cartilage to 
compressive forces, since it is rich with proteoglycans and 
collagen fibrils, which are arranged perpendicularly to the 
cartilage surface (7). This zone has the lowest water con-
tent, compared to the other zones (65% of total cartilage 
mass) (3). Right underneath the deep zone, calcified car-
tilage is situated and presents layer separating deep zone 
and subchondral bone. Cells in the calcified cartilage have 
small volume, while the matrix is rich in collagen X. The 
tide mark separates the deep zone from the calcified car-
tilage, and the cement line separates calcified cartilage 
zone and subchondral bone. The calcified zone has a cru-
cial role in fixation of the articular cartilage to the bone, 
because the collagen fibrils of the deep zone extend all the 
way to the subchondral bone and thus serve as anchors 
(4,7).
Current treatment options in 
osteoarthritis
Osteoarthritis is among the top-five causes of disabil-
ity amongst non-hospitalized adults according to esti-
mates from the National Institute of Arthritis and Mus-
culoskeletal and Skin Diseases (10). Osteoarthritis is 
typically characterized with articular cartilage degenera-
tion, low grade synovitis, and alterations in peri-articular 
soft tissues and subchondral bone (11-13). Hyaline carti-
lage is avascular and anerual, and it has limited intrinsic 
healing capacity (14). In addition, osteoarthritis affects 
mainly older patients affected with age related articular 
cartilage changes, which consequently reduce intrinsic 
regenerative abilities (15). In the case of severe osteoarthri-
tis, the only available treatment option is surgical inter-
vention i.e. joint arthroplasty resulting with pain reduc-
tion, improved range of motion within the joint and 
subsequently improved quality of life. Implants com-
prised of metal, ceramics and ultra-high molecular weight 
polyethylene are designed to allow stabile low friction 
surface with low wear properties. Main disadvantage of 
joint arthroplasty is extreme invasiveness after which no 
or little room is left for additional surgical repair in cases 
when implant failure occurs. Furthermore, it definitely 
does not represent a good solution for young patients; 
since those patients have higher physical demands and 
therefore also higher chance to experience implant failure 
in their lifetime (16). Several less invasive alternative 
methods are currently in use, such as various types of 
osteotomies, interposition arthroplasty, hemiarthroplasty, 
excisional arthroplasty and joint resurfacing. Although 
these therapeutical options leave some extra room for fur-
ther surgical repairs, they should still be considered as an 
alternative treatment, with articular cartilage repair tech-
niques allowed to become a treatment of choice. 
Since osteoarthritis usually affects large areas of hya-
line cartilage and occurs in older patients with limited 
intrinsic healing capacity, it is considered one of the great-
est challenges in the area of cartilage repair (12). It could 
be that effective cartilage repair techniques for focal ar-
ticular lesion should be developed first, for younger pa-
tients who have better intrinsic healing capacity compared 
to older population. Once such treatment will be estab-
lished, same/similar concepts could be used to in order to 
achieve significant improvement in cartilage repair in pa-
tients with osteoarthritis. Therefore, the focal articular 
lesion and the use of new technologies and concepts are 
in focus of this article.
Articular cartilage focal lesion and 
intrinsic healing capacity
The response of cartilage to trauma and its potential 
for repair depends on type of sustained injury and affec-
tion of subchondral bone (17-20). Depending on the ex-
tent of cartilage damage sustained after acute articular 
cartilage injury, we can divide the injuries into three basic 
categories (21). First category is comprised of injuries 
where extracellular matrix and/or cells are damaged, 
without visible disruption of articular surface. Usually, no 
symptoms are present, and injury cannot be detected 
macroscopically. Cartilage responds to these injuries with 
synthesis of new matrix molecules and eventually with 
cell proliferation. Only in cases where basic matrix struc-
ture sustains considerable damage, injury may progress. 
Second category includes injuries where the cartilage is 
disrupted, with intact subchondral bone, combined with 
either mechanical symptoms, joint effusions or synovitis. 
Because of intact subchondral bone, there is no blood clot 
formation; and healing potential is based on extracellular 
matrix synthesis and cell proliferation, still insufficient to 
fill the lesion gap. Third category includes cartilage inju-
ries with underlying subchondral bone disruption (osteo-
chondral fractures). These injuries may cause similar 
symptoms to those of second category, but in these inju-
ries blood clot is formed, and bone marrow cells are invad-
ing the lesion site, finally resulting with formation of the 
fibrocartilaginous tissue. Similar to the second category, 
healing capacity and lesion progress depend on lesion lo-
cation/size and joint characteristics. The full thickness 
cartilage defect in the joint lacks the intrinsic healing abil-
Articular cartilage repair techniques I. Bohaček et al.
Period biol, Vol 117, No 1, 2015. 127
ity and full spontaneous repair is almost never achieved 
(22). Furthermore, these defects are considered as impor-
tant factor for osteoarthritis development; therefore in 
those patients articular cartilage repair techniques are 
indicated and should be performed.
ARTICULAR CARTILAGE REPAIR 
TECHNIQUES
Bone marrow stimulation
Several well established bone marrow stimulation 
(BMS) techniques were developed so far, including: abra-
sion arthroplasty, subchondral drilling and microfracture. 
The basic principle of these techniques is to abrade (abra-
sion arthroplasty (23, 24)), penetrate (drilling (25) or 
microfracture (26)) the subchondral bone. These tech-
niques allow de novo tissue formation from a bone marrow 
derived blood clot situated on the lesion site. Among 
these, microfracture is currently considered as the gold 
standard technique, and it is currently the most common 
routinely preformed BMS technique. The surgical goal is 
to produce microfractures in the subchondral bone per-
pendicular to the surface and to be able to reach all areas 
of the joint with the instruments (Figure 2). The micro-
fracture technique has been demonstrated to be an effec-
tive arthroscopic treatment for full-thickness chondral 
lesions. It is cost effective, technically not complicated, 
has an extremely low rate of associated patient morbidity, 
and leaves options for further treatment. It is performed 
using various angled awls (30°, 45°, 90°) and multiple 
holes, or microfractures, are then made in the exposed 
bone about 3 to 4 mm apart. Blood and bone marrow 
start to flow into the damaged area and gradually they 
create a clot that is known as super clot. The microfracture 
technique produces a rough bone surface that the clot 
adheres to more easily. This super clot, which completely 
covers the damaged area, contains various elements, in-
cluding progenitor cells, mesenchymal stem cells, cyto-
kines and growth factors that contribute to cartilage re-
pair. Over time this clot matures and slowly transforms 
into fibrocartilage, which unfortunately is of inferior 
quality when compared to the original articular cartilage 
that joints have. However in most cases even this lower 
quality cartilage is enough for patients to return back to 
normal day activities and sports (27). 
Disadvantage of fibrocartilage is that it lacks desired 
hyaline cartilage properties i.e. structural, biomechanical 
and biochemical properties needed to provide satisfying 
long-term results (28). Indications for microfracture in-
clude full thickness (grade IV) focal articular cartilage 
defect, unstable full thickness lesion and degenerative 
knee joint lesion (as a concomitant procedure during knee 
alignment). Contraindications for microfracture treat-
ment include partial thickness defects, uncorrected axial 
malalignment (knee) and global osteoarthritis. Complica-
tions following microfracture treatment include mild 
Figure 1. Four zones of articular cartilage. Superficial, middle, deep and calcified cartilage can be easily distinguished, based on different 
distribution of chondrocytes and components of extracellular matrix.
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transient pain, recurrent joint effusions, especially when 
beginning to bear weight and decreased range of motion 
due to scarring (29).
Osteochondral autograft/allograft 
transplantation
Osteochondral autograft transfer system (OATS) and 
osteochondral allograft transplantation (OALT) represent 
a transplantation techniques in which living osteochon-
dral tissue is transplanted directly into the defect site. It 
is the only articular cartilage repair technique in which 
hyaline cartilage is provided and retained (30, 31). Such 
osteochondral tissue can be derived either from donor 
(OALT), or the patient itself (OATS). Both graft types 
are obtained using a sharp harvesting tool and further 
press-fit into a defect site. OATS grafts are usually har-
vested from non-load-bearing surfaces of the joint, e.g. 
intercondylar notch or lateral/medial trochlea above the 
linea terminalis for knee procedures; or anterior part of 
the medial or lateral talar facet for treatment of osteo-
chondral lesions in foot and ankle (32). On the other side, 
when obtaining OALT grafts, optimal donor-recipient fit 
is significantly facilitated since grafts are harvested from 
anatomically identical area on which lesion is present. 
Main indications for osteochondral grafting technique 
are treatments of focal cartilage defects, in particular os-
teochondritis dissecans (33-35) and osteonecrosis (36, 
37). In general, osteochondral grafting is indicated in 
cases of larger osteochondral defects, for cases in which 
bone involvement is greater than 6 to 10 mm deep, or in 
cases of unsuccessful previous microfracture treatment 
(38). Smaller lesions (up to 2cm2) are suitable for OATS, 
while larger lesions (2cm2 and larger) require use of OALT 
(39). Some authors have put this size limit to lesion diam-
eter of 1 cm, a size under which OATS is used, and above 
which OALT is recommended. Use of OATS autografts 
is contraindicated in “kissing” lesions, multiple compart-
ment full-thickness lesions, significant angular changes, 
history of joint infection, intraarticular fracture and rheu-
matoid arthritis (40). A few relative contraindications for 
OATS allografts can be fund in the literature, such as: 
advanced multicompartmental arthrosis, inflammatory 
arthropathies and the presence of altered bone metabo-
lism (chronic steroid use, alcohol abuse, and smoking) 
(41). Several disadvantages of these techniques were re-
ported so far, such as: limited tissue availability (auto-
grafts), donor site morbidity (autografts), questionable 
chondrocyte viability after storage (allografts), poor lat-
eral tissue integration (both, auto- and allo-graft OATS) 
and donor to patient disease transmission (allografts) (42). 
In addition, several complications may occur such as: in-
fections, loose body (in cases when graft loosens), graft 
reabsorption or cartilage degeneration if excessive pressure 
was applied during graft press fitting. Thromboembolic 
events and reflex sympathetic dystrophy may also occur 
(40).
Autologous chondrocyte implantation
In the 1970’s Swedish doctor Lars Petersen, came to 
the idea which is nowadays considered as a basic concept 
in autologous chondrocyte implantation (ACI): to culture 
autologous chondrocytes and implant them on articular 
cartilage injury site under the periosteal flap. After verify-
ing his hypothesis on the rabbit model in 1987 (43), Pe-
terson et al worked on the development of the same tech-
nique for human use. The first clinical study was published 
Figure 2. Microfracture treatment of osteochondritis disse-
cans. (A) Probatory instrument identifying osteochondral defect 
present on the capitulum of the humerus. (B) Debridement of the 
osteochondral defect using a motorized instrument. (C) Subchon-
dral bone is exposed and ready for microfracture, note that no signs 
of sclerotic bone are present; (D) Microfracture treatment per-
formed using angled awl; (E) Multiple microfractures situated 
every 3-4 mm on exposed subchondral bone; (F) After releasing 
tourniquet blood together with bone marrow start to flow into the 
damaged area. (G) Super clot formed three days after microfracture 
treatment on the site of previous osteochondral lesion on medial 
femoral condyle; (H) One year after initial microfracture treatment 
fibrocartilage is filling the osteochondral defect on medial femoral 
condyle.
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in 1994, showing efficacy of ACI for treatment of deep 
articular cartilage defects (44). The whole concept is 
nowadays considered as a revolutionary breakthrough at 
that time, which has completely changed the cartilage 
repair concept/strategies. 
ACI, frequently also referred as autologous chondro-
cyte transplantation (ACT), represents a cell-based ar-
ticular cartilage repair technique in which transplanted 
chondrocytes are used in order to allow de novo develop-
ment of the articular hyaline cartilage. Over time, origi-
nal technique was further developed, following current 
concepts and trends in cell transplantation and biomate-
rial science. These modifications of the original ACI tech-
nique are popularly known as so-called “ACI generations” 
(22, 45).
Some types of ACI techniques, regardless of the gen-
eration to which they belong, can be indicated as pri-
mary treatment choice, but they are also frequently indi-
cated in cases when other techniques have failed. Based 
on the current evidence, an indication for ACI is given for 
symptomatic cartilage defects starting from defect sizes 
of more than 3-4 cm2, up to 10 cm2; while in the case of 
young and active sports patients lower limit starts at 2.5 
cm2. ACI is also frequently indicated in cases of failed 
previous treatment, such as microfracture or osteochon-
dral grafting. Advanced osteoarthritis, “kissing” lesions 
and inflammatory arthritis represent the most important 
contraindications for ACI (39, 46). 
The “first generation” of autologous 
chondrocyte implantation
The classical ACI “first generation” is the method orig-
inally described by Brittberg et al in 1994, and consists of 
two stage procedure. In the first stage chondrocytes are 
harvested from non-load-bearing donor site of the patient 
and subsequently transferred to the laboratory in which 
cartilage is digested in order to isolate chondrocytes. The 
chondrocytes are expanded in the tissue culture until de-
sired number of differentiated cells is achieved and in the 
second stage the cells are transplanted to the patient. In 
the original procedure cells were injected beneath the 
periosteal patch harvested from patient’s proximal tibia 
and sewn over the chondral defect, in order to achieve 
complete defect filling (44, 47).  ACI provides satisfying 
long-term results with significant benefits for the patient 
in terms of pain relief, improved function and improve-
ment in life quality (48). 
Since periosteal flap is used in the original method, it 
is also known under acronym PACI (Periosteum - ACI). 
The initial idea to use periosteum was based on the as-
sumption that it has strong chondrogenic potential, on 
one side, containing mesenchymal stem cells and on the 
other side, providing growth factors needed for cartilage 
regeneration (49, 50). Despite all the beneficial effects of 
PACI, several complications of the technique were also 
described, usually related with periosteal patch. They can 
be divided to early complications: periosteal patch detach-
ment and delamination; and late complications, such as 
periosteal hypertrophy (49, 51-54). In addition, harvest-
ing the periosteal flap prolongs surgical procedure, re-
quires larger incision and it is frequently associated with 
pain on the harvesting site (55). 
In order to develop ACI technique with fewer compli-
cations, periosteal flap was replaced by collagen mem-
brane usually made of porcine derived type I/type III 
collagen (56). This method is therefore widely known as 
CACI (Collagen - ACI), the use of which results with 
lower incidence of graft hypertrophy (57, 58). 
Characterized chondrocyte implantation (CCI) is also 
designated in literature as first generation ACI technique 
since in the second stage open procedure is performed, 
periosteal flap is used, under which cultured chondro-
cytes are transplanted (22). Characterized chondrocytes 
represent an expanded population of chondrocytes, which 
expresses a marker profile (a gene score) predicting the 
capacity to form hyaline-like cartilage in vivo. This mark-
er profiling is used to enhance potency of each chondro-
cyte batch in a way of optimizing the cell expansion pro-
cedures for preserving phenotypic characteristics and 
biological activity (59, 60). In that way, a higher degree 
of homogeneity in the cartilage-forming capacity of the 
individual expanded cell populations is achieved. 
The “second generation” of autologous 
chondrocyte implantation
Both, PACI and CACI require two-stage procedure, 
and imply the chondrocyte cultivation. Once cultivated 
and transplanted, chondrocytes may be unevenly distrib-
uted within the lesion site, which represents potential 
problem in optimal cartilage repair (61). Another draw-
back of both, PACI and CACI, is potential chondrocyte 
leakage into the articular space (62). In order to overcome 
these problems, the “second generation” of ACI was devel-
oped and defined as a two-stage procedure (first stage 
arthroscopic, second stage open or arthroscopic), with 
cultivated chondrocytes implantation via cell-seeded, 
three-dimensional, bio-absorbable scaffolds (22, 63). An 
example of second generation ACI is a technique of matrix 
induced autologous chondrocyte implantation (MACI) 
(64, 65). It is based on utilizing the porcine derived type 
I/type III collagen (like in CACI) as a scaffold for in vitro 
cultured chondrocyte seeding, with subsequent autolo-
gous serum culture application before seeded scaffold in-
vivo implantation. In second ACI generation several dif-
ferent techniques and scaffolds are described and 
patented. The scaffolds include hyaluronic acid-based 
scaffold (Hyalograft C, HYAFF-11, Fidia Advanced Bio-
polymers Laboratories, Padova, Italy) (66); fibrin gel-
polymer matrix (BioSeed C, TransTissue Technologies 
GmbH, Berlin, Germany) (67); a type I collagen gel ma-
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trix (CaReS, Arthro Kinetics, Esslingen, Germany); a 
biphasic chondroitin sulfate-collagen scaffold derived 
from bovine pericardium (Novocart 3D, TETEC Tissue 
Engineering Technologies AG, Reutlingen, Germany); a 
solid agarose-alginate matrix (Cartipatch, TBF Genie 
Tissulaire, Bron, France); tissue fibrin glue (TissuCol, 
Baxter, Austria) (68); hydroxyapatite with interconnected 
pores scaffold, later embedded in 3% type I collagen atel-
locollagen gel (IP-CHA-atellocollagen gel, Koken, Tokyo, 
Japan); chondrocyte-pre-seeded fibrin 3D matrix gel 
(Chondron, Sewon Cellontech Co. Ltd., Seoul, South 
Korea) (69) and chondrocyte-pre-seeded type I/III col-
lagen membrane (ACI-Maix, Matricel GmbH, Herzo-
genrath, Germany) (22). 
The “third generation” of autologous 
chondrocyte implantation
The “third generation” ACI includes one- or two-stage 
procedures, regardless open or arthroscopic, in which in 
vitro treated chondrocytes are implanted within chondro-
inductive and chondro-conductive 3D matrices (22). Ex-
ample of third generation technique is technique per-
formed in two stages, where chondrocytes processed in 
bioreactor are further embedded into a type I collagen 
matrix from bovine origin (NeoCart, Histogenics, 
Waltham, Massachusets, USA) (70). Another example 
represents utilization of minced autologous hyaline carti-
lage spread on a 3D polyglycolic-acid-polycaprolactone 
scaffold and secured with staples (CAIS - cartilage auto-
graft implantation system, DePuy, Mitek, USA). 
Failure, reoperations and 
complications of ACI
In the literature there is large number of different 
clinical studies performed, usually proving safety and ef-
ficacy, but not many of them dealt with failure occurrence 
after ACI, prevalence of reoperations after ACI or preva-
lence and description of the complications after ACI. 
However, Harris et al (22) performed important system-
atic review and selected 82 studies comparing different 
generations and ACI techniques regarding postoperative 
complications, failure and reoperation occurrence. Inter-
estingly, even 90% of the considered studies were rated as 
poor, according to the methodology score. In addition, in 
41% of studies financial conflict of interest (COI) was 
declared, while in 22% there was no report about poten-
tial COI. According to the analysis, 5.8% of the patients 
experienced failures (1.5-7.7%), with mean of failure be-
ing 22 months, suggesting that first two years are critical 
for the failure development. Failure rates were: 7.7% for 
PACI, 3.3% for second generation, 1.5% for CACI and 
0.83% for all-arthroscopic-stages second generation ACI. 
Failure rate for all open vs arthroscopic ACI’s was 6.1% 
vs 0.83%. Overall rate of reoperation was 33%, including 
planned second look arthroscopies. Unplanned re-opera-
tion rates PACI, CACI, second-generation, and all-ar-
throscopic second-generation ACI were 27%, 5%, 5%, 
and 1.4%, respectively. Highest occurrence observed after 
PACI was usually caused by development of arthrofibro-
sis or graft hypertrophy. The number of studies/patients 
who underwent third generation techniques was too low 
and adequate analysis couldn’t be performed; therefore, 
we are still lacking clear conclusions on third ACI gen-
eration.
ACI vs microfracture
Great debate is present in last couple of years regarding 
the cost-benefit ratio between the ACI and simpler micro-
fracture method. Knutsen et al (71) have reported results 
of a randomized clinical study comparing ACI with mi-
crofracture 5 years after initial procedure. According to 
that study, both techniques provided satisfactory results 
in 77% of the patients, without significant difference in 
the clinical and radiographic results between the two 
groups. Authors suggested that further long-term follow-
up is needed. Later on, relatively recent systematic review 
was performed and ACI was compared to other treatment 
options, such as microfracture, mosaicplasty, bone mar-
row derived mesenchymal stem cells etc. (72). Seventeen 
studies were included, and according to them ACI shows 
better clinical outcomes and higher tissue quality com-
pared to microfracture. Interestingly, studies comparing 
ACI with MACI or bone marrow derived mesenchymal 
stem cells demonstrated similar results of all these meth-
ods. Altogether, in all but 2 studies ACI was demonstrat-
ed as superior treatment for cartilage defects compared to 
other treatment options. The recent systematic review 
comparing ACI and microfracture by Oussedik et al. (73) 
included 34 articles. All studies showed improvement in 
outcome scores compared to baseline values, regardless of 
the treatment modality. Authors have concluded that mi-
crofracture appears to be effective in smaller lesions and 
ACI in larger lesions. PACI has been shown to be associ-
ated with symptomatic cartilage hypertrophy more fre-
quently than CACI, while MACI was described as techni-
cally less challenging and in lesions greater than 4 cm2 it 
has shown to be more effective than microfracture (73).
In addition to above-mentioned debate, a prospective 
randomized multicentric study was performed, where 
CCI was compared to microfracture in grade III to IV 
symptomatic cartilage defects of the femoral condyles. 
This is one of the rare studies in which group of patients 
was followed and reported in literature in early-, mid- and 
long-term follow-up after initial procedure. Saris et al re-
ported that in early follow-up (one year after treatment) 
CCI was associated with a tissue regenerate that was su-
perior the one present after microfracture technique (59). 
Later, on mid-term follow-up (three years after initial pro-
cedure) clinical outcome was evaluated with serial MRI 
scans. Results have revealed that treatment of articular 
cartilage defects with CCI results in significantly better 
clinical outcome compared with microfracture. Time to 
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treatment and chondrocyte quality were also shown to 
affect the final outcome. Namely, patients with shorter 
period from symptoms onset to initial procedure and 
higher chondrocyte quality had significantly better results 
(74). Long-term clinical outcome of the same group was 
performed 5 years after initial procedure, i.e. CCI or mi-
crofracture. Clinical outcome 5 years after initial treat-
ment for CCI and microfracture were comparable. How-
ever, time to treatment has again showed to affect the final 
outcome, since in the early treatment group CCI obtained 
statistically significant and clinically relevant better re-
sults than microfracture. Delayed treatment, however, 
resulted in less predictable outcomes for CCI. Results 
provide strong evidence that time since onset of symp-
toms is an essential variable that should be taken into 
account in future treatment decision making (75).
We have to emphasize that second and third ACI gen-
erations were developed mainly in last decade, some of 
which even in last couple of years. Therefore, prospective 
randomized clinical studies are not performed yet and 
current results mainly rely on very few (frequently limit-
ed) studies, requiring additional long-term high-quality 
clinical studies to be performed, comparing all the tech-
niques with microfracture treatment, which is still the 
most widely used and most extensively analyzed articular 
repair technique.
CONCLUSION
Chondral and osteochondral focal lesions represent a 
wide spectrum of disorders for which there is no single 
effective treatment that would fulfill all the requirements 
needed for adequate restoration of cartilage structure and 
function. Currently, a great number of established and 
emerging techniques are present for treatment of such le-
sions. This review article gives insight into available treat-
ment options together with list of their indications, con-
traindications and potential complications. Having that 
in mind, an individualized approach can be created for 
each patient with a single aim: to prevent development/
progression of osteoarthritis under the high mechanical 
demand present in everyday life of an individual.
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